DOPA metabolism in neuroblastoma.

Area of Science:

• Biochemistry
• Oncology
• Pediatric Medicine

Background:

• Neuroblastoma is a pediatric cancer requiring sensitive diagnostic markers.
• Circulating biomarkers can aid in early detection and monitoring of neuroblastoma.
• DOPA (3,4-dihydroxyphenylalanine) is a precursor in catecholamine synthesis, potentially altered in neuroblastoma.

Purpose of the Study:

• To evaluate plasma DOPA levels as a diagnostic and predictive marker for neuroblastoma.
• To establish normal DOPA ranges in healthy children and those with non-neurogenic tumors.
• To assess the utility of DOPA levels in monitoring treatment response and detecting recurrence.

Main Methods:

• Radioenzymatic assay was used to quantify DOPA in blood plasma samples.
• Samples were collected from 60 neuroblastoma patients at various stages of treatment.
• Control groups included tumor-free children and those with non-neurogenic tumors.

Main Results:

• Most neuroblastoma patients (28/31) with active disease exhibited elevated plasma DOPA levels (>5.3 ng/ml).
• Successfully treated patients without evidence of disease generally had normal DOPA levels.
• Elevated DOPA levels in treated patients predicted impending clinical recurrence or persistent tumor.
• Extraordinarily high DOPA levels were observed in cerebrospinal fluid of a patient with cerebral neuroblastoma.

Conclusions:

• Plasma DOPA is a reliable predictive and diagnostic test for neuroblastoma.
• DOPA levels can aid in distinguishing neuroblastoma from other tumors.
• This assay shows promise for monitoring treatment efficacy and detecting disease recurrence.